Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Magrolimab - Forty Seven

Next Previous
Drug Profile

Magrolimab - Forty Seven

Alternative Names: 5F9; GS-4721; Hu5F9 G4; Magrolimab - Forty-Seven/Stanford-University; ONO 7913

Latest Information Update: 08 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stanford University
  • Developer Forty Seven; Gilead Sciences; M. D. Anderson Cancer Center; Merck KGaA; Merck Sharp & Dohme; National Cancer Institute (USA); Ono Pharmaceutical; Roche; Stanford University; University of California at San Francisco
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Brain cancer; Colorectal cancer; Cutaneous B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Head and neck cancer; Hodgkin's disease; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 08 Jul 2026 Discontinued - Phase-I for Colorectal cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, First-line therapy, Recurrent) in Japan (IV)
  • 08 Jul 2026 Discontinued - Phase-I for Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease) in Japan (IV)
  • 08 Jul 2026 Discontinued - Phase-I/II for Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top